FOR IMMEDIATE RELEASE
April 6, 2022
STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE
Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison
(919) 903-2057
kevin.scorsone@ncoda.org
www.ncoda.org
OHIO MAKES IT OFFICIAL: UNANIMOUS VICTORY TO BAN COPAY ACCUMULATORS
CAZENOVIA, NY – NCODA is proud to share the news that the Ohio House unanimously (86 to 0) passed a bill that is banning copay accumulator practices. House Bill 135 (HB 135) marks a long-awaited victory for copay accumulator reform in the Buckeye state. This bill had been waiting on a vote for nearly a year, another resounding reminder that hope can never be lost and the work most always be put forth in the legislative arena to ensure that patients receive the highest quality, most cost-effective care.
This bill makes sure that health insurance corporations do not exclude any amounts paid by a covered individual when calculating the individual’s contribution to any cost-sharing requirement of their health plan. These requirements do not apply for brand name drugs with generic alternatives, unless the covered individual’s prescriber determines that the brand prescription drug is medically necessary.
Important updates such as this can be found in the newly released NCODA Oncology State Legislation Tracker. This state-of-the-art and first of its kind tracker is updated weekly and features all oncology related bills from every state. The tracker includes the full bill to read, but also includes a summary and ‘why it matters’ section to educate our membership in a thorough and timely manner. Access the tracker by clicking on the link here.
NCODA believes that this bill will ensure that covered individuals will be able to obtain their prescription in an efficient manner and quality care will be achieved. We applaud the work of the Ohio legislature.
####
For any questions regarding legislative news and initiatives, e-mail Kevin Scorsone, NCODA’s Legislative & Policy Liaison, at kevin.scorsone@ncoda.org
